Inrebic

Active Ingredient(s): Fedratinib Hydrochloride
FDA Approved: * August 16, 2019
Pharm Company: * IMPACT BIOMEDICINES INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Inrebic Overview

Fedratinib (trade name Inrebic, formerly known as TG101348; SAR302503) is an orally available semi-selective inhibitor of Janus kinase 2 (JAK-2) developed for the treatment of patients with myeloproliferative diseases including myelofibrosis. Fedratinib acts as a competitive inhibitor of protein kinase JAK-2 with IC50=6 nM; related kinases FLT3 and RET are also sensitive, with IC50=25 nM and IC50=17 nM, respectively. Significantly less activity was observed against other tyrosine kinases incl...

Read more Inrebic Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fedratinib

Recent Inrebic Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Inrebic: (1 result)

Sorted by National Drug Code

• 59572-720 Inrebic 100 mg Oral Capsule by Celgene Corporation

Other drugs which contain Fedratinib Hydrochloride or a similar ingredient: (1 result)

• FEDRATINIB